Treatment News : HIV Integrase Inhibitor Dolutegravir Comparable to Isentress for First-Line Therapy - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 6, 2012

HIV Integrase Inhibitor Dolutegravir Comparable to Isentress for First-Line Therapy

by Tim Horn

AIDS 2012The experimental integrase inhibitor (INI) dolutegravir is comparable to the approved INI Isentress (raltegravir) for first-time HIV treatment takers, according to preliminary 48-week data from a Phase III clinical trial presented Thursday, July 26, at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

Dolutegravir, being developed by ViiV Healthcare in collaboration with Osaka, Japan-based Shionogi & Co., is expected to be the third INI approved for the treatment of HIV.  Merck’s twice-daily Isentress (raltegravir) was approved in 2007 for treatment-experienced people living with HIV and again in 2009 for those starting therapy for the first time. Gilead’s elvitegravir is now being reviewed by the U.S. Food and Drug Administration; it is expected to be approved for once-daily use, in combination with a boosting agent (either ritonavir or cobicistat) and as a component of the “Quad” four-in-one fixed-dose combination tablet.

In clinical trials, dolutegravir has been used once daily, without the need for boosting, and is being explored in a fixed-dose combination tablet of its own—572-Trii, which also contains ViiV’s nucleoside analogs abacavir and lamivudine.

Encouraging data from a Phase II study (SPRING-1) evaluating dolutegravir as a component of first-line HIV treatment, were presented earlier this year at the 19th Conference on Retroviruses and Opportunistic Infections.  At AIDS 2012, Francois Raffi, MD, of the University of Nantes in France and his colleagues provided delegates with a glimpse of the 48-week data from the pivotal Phase III SPRING-2 study conducted by ViiV and Shionogi.

SPRING-2 randomized 822 people on three continents—North America, Europe and Australia—to receive once-daily 50 mg dolutegravir or twice-daily 400 mg Isentress, plus a study investigator’s choice of either Truvada (tenofovir plus emtricitabine) or Epzicom (abacavir plus lamivudine). Most (85 percent) of the study volunteers were white men; roughly a quarter of the study volunteers had a pre-treatment viral load in excess of 100,000 copies and ten percent had a CD4 count below 200 cells.

At the week-48 mark, Raffi and his colleagues reported, 88 percent of those in the dolutegravir group had undetectable viral loads (below 50 copies), compared with 85 percent of those in the Isentress group. This difference, however, was not considered to be statistically significant, hence dolutegravir was classified as being “non-inferior”—no more or less effective—to Isentress.

Looking specifically at those with high pre-treatment viral loads, the researchers noted that 82 percent of those in the dolutegravir group, compared with 75 percent of those treated with Isentress, had undetectable HIV levels at week 48. Among those with lower pre-treatment viral loads, the efficacy was similar: 90 percent in the dolutegravir group, compared with 89 percent of those in the Isentress group, had undetectable HIV levels at week 48.

Approximately 5 percent of the dolutegravir-treated patients, compared with 8 percent of those who received Isentress, experienced bona fide virologic failure during the study. One patient in the Isentress group who experienced virologic failure, compared with no patients in the dolutegravir group, had evidence of HIV mutations conferring resistance to INIs.

As for adverse events, roughly 11 percent of patients in the dolutegravir group, compared with 14 percent in the Isentress group, discontinued treatment due to side effects.  The most common side effects, in both groups, were nausea, diarrhea, headache and sinus/throat inflammation.

As for laboratory abnormalities, Raffi noted that patients in the Isentress group experienced slightly higher gains in total cholesterol and triglyceride levels. Blood-based creatinine levels were higher and estimated measurements of creatinine clearance were lower—both potential markers of kidney problems—were more likely to be documented in the dolutegravir group, though patients receiving dolutegravir were no more likely to experience clear-cut signs of kidney toxicity requiring therapy discontinuation.

“At week 48,” Raffi concluded, “once-daily dolutegravir was non-inferior to twice-daily raltegravir in treatment-naive HIV-infected subjects, with no evidence of emergent resistance to dolutegravir in virologic failure.” He added: “Dolutegravir plus NRTIs could be an option for first-line HIV treatment.”

Search: dolutegravir, viiv, shionogi, integrase inhibitor, treatment-naive, isentress, raltegravir, merck, 572-Trii, raffi, aids 2012


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.